CancerDrs

Cervical Cancer clinical trials in Kansas

8 actively recruiting cervical cancer trials at 14 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • Salina Regional Health Center — Salina, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Salina Regional Health Center — Salina, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Kansas:
  • The University of Kansas Cancer Center, Investigational Drug Services — Fairway, Kansas
  • The University of Kansas Clinical Research Center — Fairway, Kansas
  • The University of Kansas Hospital — Kansas City, Kansas
  • The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
  • University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
  • Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Kansas:
  • Saint Luke's Cancer Instititute - South — Overland Park, Kansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15